• OrsoBio

  Participated · Series B · Sep 2024

  OrsoBio is advancing a portfolio of mitochondrial protonophores designed to increase energy expenditure and complement GLP-1 RA–based weight-loss therapies. Its lead oral, liver-targeted candidate TLC-6740 is in a 12-week Phase 1b trial in patients with obesity, and a prior Phase 1 in healthy subjects showed safety, dose-dependent increases in energy expenditure, and improvements in lipids and insulin-resistance markers. IND-enabling studies for two additional protonophores (TLC-1180 and TLC-1235) with distinct distribution and delivery attributes are expected to complete in 2025. TLC-1180 is described as a potent, long-acting protonophore suitable for weekly oral or subcutaneous dosing; TLC-1235 is a controlled-release mitochondrial protonophore. OrsoBio also has TLC-3595 (an ACC2 inhibitor) and TLC-2716 (an LXR inverse agonist) in Phase 2a studies for type 2 diabetes, severe hypertriglyceridemia, and MASH. The company intends to use newly raised capital to accelerate clinical development across these programs. OrsoBio is a clinical-stage biopharmaceutical company developing therapies for obesity and related metabolic disorders including type 2 diabetes, NASH, and severe dyslipidemias. The company has a portfolio of four programs spanning clinical and preclinical development that target central pathways in energy metabolism. Lead programs include a liver-targeted mitochondrial protonophore (TLC-6740) moving through Phase 1b with a planned Phase 2a, a controlled-release protonophore candidate (TLC-1235) in IND-enabling work, an ACC2 inhibitor (TLC-3595) that completed a Phase 2a and is preparing for Phase 2b, an LXR inverse agonist (TLC-2716) that completed a Phase 2a with groundwork for Phase 2b, and an ACMSD inhibitor with a development candidate selected and IND-enabling activities underway. The company says the financing will enable advancement of these programs toward key clinical milestones. OrsoBio emerged from stealth last year and was founded in 2020; following the financing it has raised $97 million in total capital.

No current team members are available.